GILD

Gilead Sciencesの空売り状況は、投資家がGilead Sciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Gilead Sciences (NASDAQ:GILD) 株価情報, 空売り情報

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program <a target="_blank" href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected" rel="noreferrer noopener">are key focus areas for potential healthcare reforms.</a>
Goldman Sachs analyst Salveen Richter, however, warns that federal Medicaid cuts could lead to stricter policies and lower drug coverage.
Per Richter, the 340B program is currently facing increased scrutiny, with proposed reforms that could potentially benefit biopharma companies by limiting eligibility for drug discounts, which would enable &#8220;transfer of profits&#8221; from providers back to biopharma.
This shift could positively impact major biopharma companies with high exposure to 340B drugs, such as Merck &amp; Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
However, the specifics of these reforms are still uncertain, which could cause &#8220;volatility&#8221; in the healthcare sector until more details are released.
At the same time, Medicaid funding and eligibility changes are under consideration as potential cost-saving measures by the new administration.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline" rel="noreferrer noopener">AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline</a>
These changes could have negative effects on biopharma companies with significant Medicaid drug exposure, including AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Gilead Sciences, and Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), whose top Medicaid drugs make up a large percentage of their US sales.
Overall, for the 340B program, the analyst sees potential policy/legal outcomes that would move dynamics towards a transfer of profits from providers to biopharma companies as a positive for much of the biopharma sector.
Meanwhile, potential Medicaid changes could create &#8220;potential headwinds&#8221; for healthcare providers and biopharma companies, though the exact effects remain uncertain.
The healthcare industry is awaiting further clarity on these proposed policy changes and their implications.
Overall, the analyst notes that exposure to Medicaid and 340B can vary widely by product and indication.
The top three highest-spend drugs for Medicaid (as of 2022) are AbbVie&#8217;s Humira, Gilead&#8217;s Biktarvy and Eli Lilly&#8217;s Trulicity for type 2 diabetes and cardiovascular disease.
For these drugs, Medicaid and 340B spending represented ~15-30% of the drugs' FY22 and FY23 revenue.
Further, 340B impact may vary for different methods of administration within the same indication &#8211; for example, Gilead&#8217;s expects lower 340B exposure for injectables for PrEP than for daily orals &#8211; and expansion of eligibility for 340B discounts may have an outsized impact on certain therapeutics over others.
Overall, 340B reform would serve as a tailwind to biopharma, as the aforementioned initiatives are generally intended to limit access to the statutory discount.
On the other hand, spending cuts to Medicaid could have a negative impact to volume if they have the effect of reducing coverage, the analyst writes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43308041/chevron-ge-vernova-engine-no-1-bet-big-on-ai-power-but-is-it-too-late" target="_blank" rel="noreferrer noopener">Chevron, GE Vernova Bet Big On AI Power: Data Centers To Consume Enough Natural Gas To Power 3.5 Million Homes</a></li>
</ul>

Equities

News

Markets

Analyst Ratings

Movers

Trading Ideas

General

ABBV

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return of 13.3%. Currently, Gilead Sciences has a market capitalization of $121.75 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,201.60 today based on a price of $97.69 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738341013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value
TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4351485-1&amp;h=3797028251&amp;u=https%3A%2F%2Fwww.cognizant.com%2Fus%2Fen&amp;a=Cognizant">Cognizant</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) has announced an expansion of its longstanding relationship with biopharmaceutical leader <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4351485-1&amp;h=2804915010&amp;u=https%3A%2F%2Fwww.gilead.com%2F&amp;a=Gilead+Sciences">Gilead Sciences</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases. The expanded agreement aims to deliver greater cost leadership and productivity enhancement for Gilead while seeking to extract greater value from the existing relationship. Leveraging machine learning and generative AI within an agentic framework, the work addresses multiple use cases across customer service, employee interactions, and business value management. Gilead is expected to enhance its efficiency through leveraging Cognizant's expertise in AI and advanced technology applications. By deploying these cutting-edge solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.

CTSH

Cognizant And Gilead Expand Partnership To Drive Greater Value Through Advanced Technology Applications

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Gilead Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 40%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $258,167, and 5 are calls, for a total amount of $348,257.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $95.0 to $97.5 for Gilead Sciences over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Gilead Sciences's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Gilead Sciences's whale activity within a strike price range from $95.0 to $97.5 in the last 30 days. 
<h3>Gilead Sciences Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738171831_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.2</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$95.00</td>
<td>$152.5K</td>
<td>5.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$7.9</td>
<td>$7.85</td>
<td>$7.85</td>
<td>$97.50</td>
<td>$124.0K</td>
<td>11</td>
<td>261</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.15</td>
<td>$5.0</td>
<td>$5.05</td>
<td>$97.50</td>
<td>$83.3K</td>
<td>664</td>
<td>166</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$0.73</td>
<td>$0.72</td>
<td>$0.73</td>
<td>$96.00</td>
<td>$53.5K</td>
<td>561</td>
<td>784</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.55</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$97.50</td>
<td>$46.0K</td>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Where Is Gilead Sciences Standing Right Now?</h3>
<ul>
<li>With a volume of 2,022,026, the price of GILD is up 2.05% at $95.77. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About Gilead Sciences</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $114.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Morgan Stanley has upgraded their rating to Overweight and adjusted the price target to $113. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Gilead Sciences with a target price of $115. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At Gilead Sciences's Recent Unusual Options Activity

Analysts' ratings for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) over the last quarter vary from bullish to bearish, as provided by 22 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of $99.32, a high estimate of $125.00, and a low estimate of $80.00. This current average reflects an increase of 14.23% from the previous average price target of $86.95. 
<img src="https://www.benzinga.com/files/images/story/2025/1738159272_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Gilead Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$109.00</td>
<td>-</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$96.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$97.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Gilead Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Gilead Sciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gilead Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>Unveiling the Story Behind Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Key Indicators: Gilead Sciences's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 7.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 6.82%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.32% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.26.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Gilead Sciences: 22 Analysts Share Their Views

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $105 to $115.

Price Target

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $115

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.74% on an annualized basis producing an average annual return of 13.14%. Currently, Gilead Sciences has a market capitalization of $118.77 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $11,675.34 today based on a price of $95.30 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738010711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$1.00</td>
<td>$25.0K</td>
<td>2.7K</td>
<td>5.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$56.9K</td>
<td>4.9K</td>
<td>1.4K</td>
</tr>
<tr>
<td>SMMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$265.4K</td>
<td>4.0K</td>
<td>348</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$320.00</td>
<td>$41.4K</td>
<td>516</td>
<td>213</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$63.0K</td>
<td>2.9K</td>
<td>153</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$430.00</td>
<td>$52.3K</td>
<td>11</td>
<td>91</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.00</td>
<td>$37.9K</td>
<td>1.3K</td>
<td>40</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$60.00</td>
<td>$29.0K</td>
<td>33</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For SLS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>), we notice a call option sweep that happens to be bullish, expiring in 725 day(s) on January 15, 2027. This event was a transfer of 500 contract(s) at a $1.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $50.0 per contract. There were 2779 open contracts at this strike prior to today, and today 5080 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option trade with bearish sentiment. It expires in 32 day(s) on February 21, 2025. Parties traded 227 contract(s) at a $145.00 strike. The total cost received by the writing party (or parties) was $56.9K, with a price of $251.0 per contract. There were 4980 open contracts at this strike prior to today, and today 1483 contract(s) were bought and sold. 
• For SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we notice a put option sweep that happens to be neutral, expiring in 361 day(s) on January 16, 2026. This event was a transfer of 84 contract(s) at a $50.00 strike. This particular put needed to be split into 52 different trades to become filled. The total cost received by the writing party (or parties) was $265.4K, with a price of $3160.0 per contract. There were 4074 open contracts at this strike prior to today, and today 348 contract(s) were bought and sold. 
• Regarding MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we observe a call option sweep with bearish sentiment. It expires in 32 day(s) on February 21, 2025. Parties traded 30 contract(s) at a $320.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.4K, with a price of $1360.0 per contract. There were 516 open contracts at this strike prior to today, and today 213 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 361 day(s) on January 16, 2026. Parties traded 60 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $63.0K, with a price of $1050.0 per contract. There were 2977 open contracts at this strike prior to today, and today 153 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a put option trade with bearish sentiment. It expires in 32 day(s) on February 21, 2025. Parties traded 34 contract(s) at a $430.00 strike. The total cost received by the writing party (or parties) was $52.3K, with a price of $1540.0 per contract. There were 11 open contracts at this strike prior to today, and today 91 contract(s) were bought and sold. 
• Regarding TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on January 17, 2025. Parties traded 17 contract(s) at a $7.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $37.9K, with a price of $2230.0 per contract. There were 1306 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• Regarding GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we observe a call option trade with bearish sentiment. It expires in 3 day(s) on January 17, 2025. Parties traded 9 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $3230.0 per contract. There were 33 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MDGL

SMMT

TGTX

VRTX

8 Health Care Stocks Whale Activity In Today's Session

<a href="https://www.gov.uk/government/news/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness#:~:text=Press%20release-,Seladelpar%20approved%20to%20treat%20adult%20patients%20in%20the%20UK%20with,of%20seladelpar%20under%20close%20review.&amp;text=Seladelpar%20belongs%20to%20a%20group,proliferator%2Dactivated%20receptor%20delta%20agonists.">https://www.gov.uk/government/news/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness#:~:text=Press%20release-,Seladelpar%20approved%20to%20treat%20adult%20patients%20in%20the%20UK%20with,of%20seladelpar%20under%20close%20review.&amp;text=Seladelpar%20belongs%20to%20a%20group,proliferator%2Dactivated%20receptor%20delta%20agonists.</a>
&nbsp;
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called Primary Biliary Cholangitis (PBC), including pruritus. It works by controlling liver problems in the body and making the liver less inflamed&nbsp;
Seladelpar belongs to a group of medicines called peroxisome proliferator-activated receptor delta agonists. The medicine can only be prescribed to adult patients with PBC, including pruritus, in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.&nbsp;&nbsp;
<h4>Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said:&nbsp;</h4>
"Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.&nbsp;&nbsp;
"We're assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all products, we will keep its safety under close review."&nbsp;
Seladelpar's recommended dosage is one capsule (10 mg) once daily. The efficacy of seladelpar was primarily demonstrated in patients during a 12-month trial, where the medicine was studied in patients with PBC who had an inadequate response or intolerance to UDCA.&nbsp;
As with any medicine, the MHRA will keep the safety and effectiveness of seladelpar under close review.  Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (<a href="https://yellowcard.mhra.gov.uk/">https://yellowcard.mhra.gov.uk/</a>) or by searching the Google Play or Apple App stores for MHRA Yellow Card.

Biotech

"Seladelpar Approved To Treat Adult Patients In The UK With Liver Illness; As With Any Medicine, The MHRA Will Keep The Safety And Effectiveness Of Seladelpar Under Close Review" - UK Gov

-Reuters, citing conference presentation

Health Care

Gilead Exec Says Co Expects To Do "Something Like A Cymabay Acquisition Every Couple Of Years

<ul>
<li>-- Strategic Partnership Strengthens Gilead's Inflammation Research Portfolio with the Addition of LEO Pharma's Preclinical Oral STAT6 Program, Including Targeted Protein Degraders --</li>
<li>-- Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. --</li>
<li>-- LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology --</li>
</ul>

Reported Saturday, Gilead And LEO Pharma Join Forces To Accelerate Oral STAT6 Development For Inflammation And Dermatology

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Matthew Harrison upgraded the rating for Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Equal-Weight to Overweight and raised the price target from $87 to $113. Gilead Sciences shares closed at $89.14 on Wednesday. <a href="https://www.benzinga.com/quote/GILD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jon Tower upgraded McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) from Neutral to Buy and boosted the price target from $311 to $334. McDonald&#8217;s shares closed at $286.90 on Wednesday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham analyst Tom Nikic upgraded the rating for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Hold to Buy and announced a $475 price target. Lululemon shares closed at $392.92 on Wednesday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Jay Sole upgraded Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) from Neutral to Buy and raised the price target from $280 to $360. Burlington Stores shares closed at $285.95 on Wednesday. <a href="https://www.benzinga.com/quote/BURL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Anna Andreeva upgraded the rating for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Neutral to Overweight and raised the price target from $72 to $90. Nike shares closed at $71.29 on Wednesday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Nike stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-1024x549.png" alt="" class="wp-image-728650" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Upgrades

BURL

LULU

This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Morgan Stanley analyst Matthew Harrison upgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Equal-Weight to Overweight and raises the price target from $87 to $113.

Morgan Stanley Upgrades Gilead Sciences to Overweight, Raises Price Target to $113

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

Analyst Color

Large Cap

AMGN

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Galapagos NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) has unveiled plans to divide its operations into two entities, aiming to enhance shareholder value and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42866548/galapagos-to-unlock-shareholder-value-by-declaring-its-intent-to-separate-into-two-publicly-traded" rel="noreferrer noopener">sharpen strategic focus</a>.
One entity, referred to as SpinCo, will prioritize developing innovative medicines through transformational transactions, while the core Galapagos company will focus on its global cell therapy leadership in oncology.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40558289/major-investor-says-galapagos-is-undervalued-plans-to-push-on-companys-performance-and-strategic-" rel="noreferrer noopener">Major Investor Says Galapagos Is &#8216;Undervalued,&#8217; Plans To Push On Company&#8217;s &#8216;Performance&#8217; And &#8216;Strategic Opportunities&#8217;</a>
Under the separation plan, SpinCo will have approximately $2.53 billion (2.45 billion euro) of Galapagos&#8217; cash reserves.
It will target oncology, immunology and virology through strategic business deals. SpinCo intends to list its shares on Euronext, with Galapagos shareholders receiving proportional shares of SpinCo. The division will require shareholder approval, with completion anticipated by mid-2025.
As part of the separation, Galapagos will amend its 2019 global Option, License and Collaboration Agreement (OLCA) with Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>).
The updated terms grant Galapagos full global development and commercialization rights to its pipeline, subject to royalties on certain product sales.
After the split, the OLCA will apply exclusively to SpinCo. Gilead will hold a 25% stake in both companies post-separation and maintain representation on SpinCo's board.
Galapagos CEO Paul Stoffels emphasized the separation&#8217;s role in accelerating innovation and growth. He highlighted Galapagos&#8217; renewed focus on its decentralized cell therapy platform, which has shown promise in treating relapsed/refractory non-Hodgkin lymphoma.
To align with this vision, Galapagos plans to exit its small molecule discovery programs and seek partners for related assets, including the TYK2 inhibitor GLPG3667, currently in Phase 2 trials.
The restructuring will result in approximately 300 job reductions across Europe, with significant impacts in Belgium and the closure of its French site.
Galapagos expects to operate from key hubs in the U.S., Netherlands and Belgium, aiming to streamline operations and reduce annual cash burn to 175-225 million euros.
Galapagos anticipates completing the spin-off by mid-2025.
Price Action: GLPG stock is
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42877648/ebay-shares-surge-after-meta-launches-integration-test-for-facebook-marketplace" target="_blank" rel="noreferrer noopener">eBay Stock Surges After Meta Launches Integration Test For Facebook Marketplace</a></li>
</ul>
Photo courtesy of company

GLPG

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus

CGEN

Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has fallen 6.38% since its last report. The company recently reported that it has 21.98 million shares sold short, which is 1.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736272822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Gilead Sciences's Recent Short Interest

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.41% on an annualized basis producing an average annual return of 12.85%. Currently, Gilead Sciences has a market capitalization of $113.70 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a price of $91.23 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736201708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Rep. Marjorie Taylor Greene (R-Ga.) disclosed recent purchases of several stocks on Christmas Eve, according to <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene">Benzinga Government Trades.</a>
Here's a look at what the far-right politician bought.
What Happened: Greene has been an active trader of stocks while in Congress, based on her disclosures over the years.
After going several years without disclosing any trades, Greene <a href="https://www.benzinga.com/markets/equities/24/05/38611874/marjorie-taylor-greene-reveals-new-stock-trades-after-2-year-gap-berkshire-hathway-goldman-sachs">disclosed several purchases</a> in May. She also made<a href="https://www.benzinga.com/government/24/11/41754747/is-marjorie-taylor-greene-betting-on-trump-victory-buys-apple-meta-tesla-stocks-ahead-of-2024-electi"> multiple transactions</a> later in September, October and November.
Greene recently disclosed multiple stock purchases that happened on Dec. 24. Here are the trades that she made, with each valued between $1,000 and $15,000:
<ul>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</li>
<li>Johnson and Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>)</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
</ul>
Of these stocks bought in the latest disclosures, Eli Lilly, Gilead and Norfolk Southern are new buys for Greene over the last two years.
The rest of the stocks are already owned by Greene with her adding to her position. Several of the stocks, like Hershey have been bought four times by Greene in 2024.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The trading activity of <a href="https://www.benzinga.com/topic/congress-trading">members of Congress </a>continues to be a hot-button item closely monitored by retail investors and the public.
President Joe Biden <a href="https://www.benzinga.com/24/12/42538504/biden-endorses-ban-of-congressional-stock-trading-nobody-in-the-congress-should-be-able-to-make-money-in-the-stock-market-while-in-office">endorsed a ban</a>, suggesting Congress members shouldn&#8217;t be able to trade stocks and options while in office.
&#8220;Nobody in the Congress should be able to make money in the stock market while they&#8217;re in the Congress,&#8221; Biden said in an interview with political advisor&nbsp;Faiz Shakir.
There have been numerous calls to vote for Congress members to vote for a ban on Congressional trading, but a vote has not happened. Representative&nbsp;Ro Khanna&nbsp;(D-Calif.)&nbsp;<a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin" target="_blank" rel="noreferrer noopener">previously told Benzinga&nbsp;</a>that he will continue to advocate for a vote to ban the practice.
Congressional committee assignments can create conflicts of interest when trades are disclosed. Greene serves on the House Subcommittee on Cybersecurity, Information Technology, and Government Innovation, which could give her information on government contracts for technology companies.
Greene's latest stock purchases in November and the new disclosures show a continued bet on technology stocks going forward. Chip stocks and technology companies were among&nbsp;<a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r" target="_blank" rel="noreferrer noopener">the best performing&nbsp;</a>in the S&amp;P 500 in 2017, Trump&#8217;s first year in the White House previously.
Tech giants Meta and Microsoft remain popular for Greene in 2024 with multiple purchases made. A pending ban of TikTok could benefit Meta in 2025.
Greene is also positioning her portfolio with several healthcare names like Eli Lilly, Gilead and Johnson and Johnson.
A deal between Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) and Hershey could benefit Greene if the chocolate company <a href="https://www.benzinga.com/ma/24/12/42496403/deal-dispatch-hershey-monelez-houlihan-intevac-onion-infowars">approves an acquisition</a>.
While Greene has been actively buying stocks over the last several months, she has not reported selling her shares of Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), the Trump co-founded media company that completed a SPAC merger earlier this year.
Greene <a href="https://www.benzinga.com/government/24/09/41031499/marjorie-taylor-greene-stays-loyal-to-trump-keeps-djt-stock-buys-into-warren-buffetts-berkshire-in-l">disclosed buying</a>&nbsp;Digital World Acquisition&nbsp;shares back in October 2021, the SPAC that took&nbsp;Trump's&nbsp;media company public in March 2024.
The transaction was done with shares trading between $67.96 to $118.80. A tweet from UnusualWhales pins the purchase price at $94.20, meaning Greene is down significantly on her $15,000 to $50,000 purchase in the Trump-linked stock. Shares of DJT trade at $39.13 at the time of writing.
Previous disclosures by Greene have shown buys of Tesla and Berkshire Hathaway stock. Greene's portfolio currently consists of investments tied to some of the richest people in the world including Elon Musk, Warren Buffett, Jeff Bezos, Mark Zuckerberg and Jensen Huang. Her portfolio also has exposure to Trump via his media company.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/01/36459015/10-best-stock-traders-in-congress-in-2023-spoiler-nancy-pelosi-is-back-on-the-list">10 Best Stock Traders In Congress In 2023 (Spoiler: Nancy Pelosi Has Reentered The Chat)</a></li>
</ul>
Image: Shutterstock

Politics

ADBE

AMAT

AMZN

MDLZ

MSFT

NVDA

Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

ELAN

IDXX

PRGO

TEVA

VTRS

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth. Thus, investing in fundamentally stable stocks, Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD), could be a wise way to capitalize on the industry's growing momentum. Read more… With rapid innovations in biotechnology, companies are developing improved therapies and diagnostic tools addressing chronic diseases and improving patient outcomes. Moreover, the inclusion of modern tools like artificial intelligence and robotics are also contributing towards shifting gears for the biotech industry.
Amid this backdrop, investing in fundamentally stable biotech stocks, Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) could be the move for investors looking to capitalize on the sector's expansion.
The biotechnology industry is experiencing considerable growth, driven by increasing demand for personalized medicine and breakthroughs in treating chronic diseases. The approval of <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">50 novel drugs</a> by the U.S. FDA in 2024 alone showcases the sector's prospects in the coming years.
That being said, rapid drug discovery and well-timed results could not have been possible without the inclusion of modern technology in the production and R&amp;D fields. As the <a href="https://www.mckinsey.com/featured-insights/the-next-normal/biotech">AI-driven drug discovery industry</a> continues to grow, newer and more advanced pipelines are being discovered in a shorter amount of time, resulting in a more expanded reach for the biotech sector.
Additionally, there has been a new contender for aiding us with the required capabilities to advance our drug-producing and research capabilities- <a href="https://www.nne.com/techtalk/robotic-solutions-are-changing-the-game-of-biotech/">Robotics</a>. Robotics has advanced the field by reducing human errors like repeatability, accuracy, and sterility, and aiding us in a safer and more efficient production process.
In line with these positive trends, a study by Precedence Research forecasts the global biotechnology market to reach $4.61 trillion by 2034, growing at a <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion,USD%20521.02%20billion%20in%202023.">CAGR of 11.5%</a>.
Now, let us dive deep into the fundamentals of three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, starting with #3.
Stock #3: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a biotechnology company that is developing and commercializing therapies for treating cystic fibrosis (CF). It offers TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO.
On January 10, 2025, VRTX <a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-and-zai-lab-announce-strategic-agreement-develop-and">announced an exclusive collaboration</a> and license agreement with Zai Lab Limited (<a href="https://stocknews.com/stock/ZLAB/">ZLAB</a>) to develop and commercialize VRTX's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore.
The collaboration could enhance VRTX's market presence in the respective regions and drive sales growth.
On December 20, 2024, VRTX <a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-alyftrektm-once-daily-next">announced U.S. FDA approval</a> of ALYFTREK for the treatment of CF in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK.
The approval strengthens the company's pipeline for the treatment of CF and related conditions and enhances its market presence.
For the fiscal 2024 third quarter that ended September 30, VRTX's net product revenues increased 11.6% year-over-year to $2.77 billion. Its non-GAAP operating income rose 11.4% from the year-ago value to $1.31 billion.
Additionally, the company's non-GAAP net income and non-GAAP net income per share grew 7.5% and 7.4% from the prior year's quarter to $1.14 billion and $4,38, respectively.
Analysts expect VRTX's revenue for the fiscal year ending December 2025 to increase 8.4% year-over-year to $11.80 billion. Its EPS for the same period is expected to rise significantly from the prior year to $18.73. Moreover, the company has surpassed the consensus revenue and EPS estimates in three of the four trailing quarters.
VRTX's shares surged 8% over the past month and 11.4% over the past nine months to close the last trading session at $441.52.
VRTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its sound fundamentals. The stock has an overall rating of B, translating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
VRTX has a B grade for Value. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, VRTX is ranked #32 out of 332 stocks.
To access VRTX's Sentiment, Growth, Momentum, Growth, and Stability ratings, <a href="https://stocknews.com/stock/VRTX/">click here</a>.
Stock #2: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics. The company's product offerings include Enbrel, Otezla, Prolia, XGEVA, Repatha, Nplate, KYPROLIS and more for treating different conditions.
On January 17, 2025, AMGN <a href="https://investors.amgen.com/news-releases/news-release-details/fda-approves-lumakrasr-sotorasib-combination-vectibixr">announced U.S. FDA approval</a> of LUMAKRAS&#xAE; (sotorasib) in combination with Vectibix&#xAE; (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer. The approval strengthens the company's portfolio of offerings for its cancer treatment pipeline.
On December 5, 2024, AMGN <a href="https://investors.amgen.com/news-releases/news-release-details/amgen-announces-1-billion-manufacturing-expansion-north-carolina">announced a $1 billion expansion</a> to establish a second drug substance manufacturing facility in North Carolina. The expansion is aimed at enhancing the company's manufacturing network to meet the growing demand for its innovative therapies along with contributing to the local economy.
For the fiscal 2025 third quarter that ended September 30, AMGN's <a href="https://www.investopedia.com/terms/r/revenue.asp">total revenues</a> increased 23.2% year-over-year to $8.50 billion. Its non-GAAP operating income rose 18.8% from the year-ago value to $4.03 billion.
Moreover, the company's non-GAAP net income and non-GAAP EPS grew 13.4% and 12.5% from the prior year's quarter to $3.02 billion and $5.58, respectively.
Street expects AMGN's revenue and EPS for the fiscal 2024 fourth quarter that ended in December to increase 8.2% and 7.7% year-over-year to $8.87 billion and $5.07, respectively. Additionally, the company has surpassed consensus revenue and EPS estimates in three of the four trailing quarters.
Shares of AMGN surged 7.3% over the past month to close the last trading session at $281.68.
AMGN's POWR Ratings reflect its robust prospects. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
AMGN has a B grade for Quality and Growth. Within the Biotech industry, it is ranked #18 out of 332 stocks.
In addition to the POWR Rating highlighted above, you can check AMGN's ratings for Value, Stability, Sentiment, and Momentum <a href="https://stocknews.com/stock/AMGN/">here</a>.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. The company's offerings include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs for the treatment of HIV/AIDS, COVID-19, viral hepatitis and more.
On January 11, 2025, GILD <a href="https://investors.gilead.com/news/news-details/2025/Gilead-and-LEO-Pharma-Enter-Into-Strategic-Partnership-to-Accelerate-Development-of-Oral-STAT6-Program-With-Potential-in-Multiple-Inflammatory-Diseases/default.aspx">announced a strategic partnership</a> with LEO Pharma to accelerate the development and commercialization of LEO's small molecule oral STAT6 programs for the potential treatment of patients with inflammatory diseases.
The collaboration could enhance GILD's portfolio of treatment of inflammatory diseases and enhance the company's market position.
On December 17, 2024, GILD <a href="https://investors.gilead.com/news/news-details/2024/U.S.-FDA-Grants-Breakthrough-Therapy-Designation-to-Trodelvy-sacituzumab-govitecan-hziy-for-Second-Line-Treatment-of-Extensive-Stage-Small-Cell-Lung-Cancer/default.aspx">announced a U.S. FDA grant</a> for Breakthrough Therapy Designation to Trodelvy&#xAE; aimed at the treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy.
The development could enhance Trodelvy's results through expediting the development and regulatory review of investigational treatments and enhance the company's portfolio.
For the fiscal third quarter that ended September 30, 2024, GILD's total revenues increased 7% year-over-year to $7.55 billion. Its non-GAAP operating income rose 1.1% from the year-ago value to $3.26 billion.
Furthermore, non-GAAP net income attributable to GILD and non-GAAP EPS amounted to $2.53 billion and $2.02, respectively.
The consensus revenue estimate of $28.41 billion for the fiscal year ending December 2025 reflects a marginal year-over-year rise. Its EPS for the same period is expected to increase 72.3% year-over-year to $7.59. Additionally, the company has surpassed consensus revenue estimates in all four trailing quarters.
GILD's shares have surged 23% over the past six months and 45% over the past nine months to close the last trading session at $95.59.
GILD's strong fundamentals are mirrored in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
GILD has a B grade for Growth, Value, Sentiment, and Quality. It has topped the 332-stock Biotech industry.
<a href="https://stocknews.com/stock/GILD/">Click here</a> to access GILD's Stability and Momentum ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
&nbsp;
<hr />
AMGN shares were unchanged in premarket trading Thursday. Year-to-date, AMGN has gained 8.07%, versus a 2.68% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aritra_Gangopadhyay</h2> <img src='https:/wp-content/uploads/2025/01/Aritra_Gangopadhyay.png' style="float:left; padding:5px;width:125px;">Aritra is a financial journalist dedicated to breaking down complex financial topics into simple, actionable insights. Holding a Master's degree in Economics, he uses his analytical expertise to help investors uncover unique opportunities for long-term success.<a href="https://stocknews.com/authors/?author=aritra-gangopadhyay">More...</a>The post <a href=https://stocknews.com/news/amgn-gild-vrtx-zlab-3-biotech-stocks-revolutionizing-healthcare/>3 Biotech Stocks Revolutionizing Healthcare</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Revolutionizing Healthcare

Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to unlo...

Cognizant, Gilead expand relationship

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out… In the fast-growing biotechnology sector, driven by advances in gene editing, personalized medicine, and artificial intelligence, companies are racing to develop new treatments for an aging population and the increasing demand for healthcare. Among the innovators in this space, Exelixis, Inc. (<a href="https://stocknews.com/stock/EXEL/">EXEL</a>) is gaining significant attention, and for good reason.
Exelixis is zeroing in on difficult-to-treat cancers armed with a clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs), and other biotherapeutics. The company leverages cutting-edge science, strategic collaborations, and significant investments to broaden its reach across various tumor types.
EXEL delivered exceptional results in its fiscal <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-third-quarter-2024-financial-results-and">third quarter</a>, surpassing analyst expectations while demonstrating the strength of its cancer-focused portfolio. The company's flagship product, CABOMETYX&#xAE;, continues to make waves alongside promising treatments like Zanzalintinib, XB010, and XL495. With many of these therapies still in trial phases or awaiting FDA approvals, EXEL is relentlessly working to improve treatment options.
In terms of price performance, the stock has returned 17.4% in the past three months, while over the past year, it rose by an impressive 47.9%, closing the last trading session at $32.73.
As we look ahead, 2025 could be a defining year for Exelixis. With a robust pipeline and an ongoing push for innovation, this company is on track for more clinical and regulatory milestones. But is EXEL a biotech stock worth adding to your portfolio?
Let's explore the factors that could shape the company's performance in the near future.
A Robust Pipeline Beyond Cabometyx
Exelixis isn't resting on its laurels with the success of CABOMETYX&#xAE;. The company is aggressively expanding its oncology portfolio with promising candidates like zanzalintinib, a next-generation oral tyrosine kinase inhibitor (TKI). This drug is being tested in the STELLAR-303 study, where it's combined with Tecentriq to treat advanced colorectal cancer. With enrollment now complete, early results from this pivotal trial are anticipated in 2025, potentially opening new doors for treatment options in a challenging cancer type.
Adding to its momentum, EXEL recently <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-merck-sign-clinical-development-collaboration">partnered</a> with pharmaceutical heavyweight Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>) to explore zanzalintinib's potential combined with MRK's blockbuster PD-1 therapy Keytruda (pembrolizumab). This collaboration spans several studies, including a late-stage trial for head and neck squamous cell carcinoma (HNSCC) and a phase I/II trial using Merck's hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, Welireg, for renal cell carcinoma (RCC).
By diversifying its pipeline, EXEL is reducing its reliance on CABOMETYX&#xAE; and aiming for long-term growth. These efforts could pave the way for a new wave of therapies that improve outcomes for cancer patients worldwide.
Robust Financials and Upbeat Guidance
During the third quarter that ended September 30, 2024, EXEL's total revenue increased 14.3% year-over-year to $539.54 million. Its income from operations income came in at $136.07 million compared to a year-ago loss of $17.58 million.
In addition, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $135.66 million or $0.47 per share, reflecting a considerable improvement from $32.09 million or $0.10 per share, respectively, recorded in the same period last year.
Recently, the company announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for the fiscal year 2025, and delivered an update on its business. Total revenues are projected to be between $2.15 billion and $2.25 billion (previous guidance: $1.975-$2.075 billion). Net product revenues are estimated to be in the band of $1.95-$1.2.05 billion (previous guidance: $1.65-$1.75 billion).
Solid Historical Growth
EXEL's revenue and EBITDA have grown at respective CAGRs of 18.4% and 45% over the past three years. The company's EBIT has increased 46.3% over the same timeframe, while its net income and EPS have improved at CAGRs of 41.7% and 44.8%, respectively.
Also, the company's total assets and levered free cash flow have grown at CAGRs of 6.5% and 25.6% over the past three years, respectively.
Favorable Analyst Estimates
Analysts expect EXEL's EPS for the fourth quarter (ended December 2024) to increase 56.7% year-over-year to $0.42. Its revenue for the same quarter is expected to come in at $558.60 million, reflecting a growth of 16.5% from the prior year. Furthermore, the company has surpassed the consensus EPS and revenue estimates in three of the trailing four quarters, which is promising.
Additionally, Street expects the company's revenue and EPS for the fiscal year (ending December 2025) to increase 3.6% and 8.6% year-over-year to $2.23 billion and $1.89, respectively.
High Profitability
EXEL's trailing-12-month gross profit margin of 96.25% is 65.9% higher than the respective industry average of 58%. Its trailing-12-month EBIT margin of 29.22% is significantly higher than the industry average of 2.39%.
Furthermore, the stock's trailing-12-month net income, ROCE, and ROTA of 22.43%, 20.20%, and 15.77% favorably compare to the negative industry averages of 4.61%, 40.27%, and 26.01%, respectively. Similarly, its trailing-12-month levered FCF margin of 20.72% is considerably higher than the industry average of 2.50%.
POWR Ratings Reflect Promise
EXEL's robust prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. EXEL has an A grade for Value and Quality, which is in sync with its lower-than-industry valuations and robust profitability, respectively.
Also, the stock has a B grade for Growth, consistent with its strong financial performance and historical growth.
Among the 333 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, EXEL is ranked #3. Beyond what I have stated above, we have also given EXEL grades for Momentum, Sentiment, and Stability. Get access to all the EXEL ratings <a href="https://stocknews.com/stock/EXEL/">here</a>.
Bottom Line
EXEL reported better-than-expected financial results for the third quarter. Analysts appear bullish about the company's growth prospects, driven by robust demand for its quality and diverse product offerings, expanding pipeline, strategic collaborations, and strong market position. Also, its growing revenue and gross profit margin depict solid financial health.
Given EXEL's solid financials, accelerating profitability, and promising growth outlook, this stock could be an ideal buy now.
How Does Exelixis, Inc. (EXEL) Stack Up Against Its Peers?
While EXEL has an overall POWR Rating of A, investors could also check out these other stocks within the Biotech industry with A (Strong Buy) or B (Buy) ratings: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>), and Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>).
For exploring more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
EXEL shares were trading at $32.83 per share on Tuesday afternoon, up $0.10 (+0.31%). Year-to-date, EXEL has declined -1.41%, versus a 3.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/exel-gild-jazz-otsky-mrk-is-exelixis-a-biotech-stock-worth-adding-to-your-portfolio/>Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?

EXEL

JAZZ

OTSKY

ZLAB

Press Releases

Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Gilead Sciences to Present at Upcoming Investor Conference

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Comments

Gilead Sciences

空売り

Gilead Sciences (NASDAQ:GILD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル